BD said worldwide revenues rose 1.6% to $5.252 billion for the 3 months ended December 31, 2025, compared with the prior-year period. Operating cash flow for the first 3 months of fiscal 2026 was $657 million.

10-QQuarterly reportFiled Feb 9, 2026Period of report Dec 31, 2025Summary published (UTC) Oct 2, 2026

Key points

AI summary

BD said worldwide revenues rose 1.6% to $5.252 billion for the 3 months ended December 31, 2025, compared with the prior-year period. Operating cash flow for the first 3 months of fiscal 2026 was $657 million.
The company paid cash dividends of $299 million to common shareholders in the first 3 months of fiscal 2026 and repurchased about $250 million of common stock. It said it expects to use about $2 billion of the cash distribution received in the Waters transaction for accelerated share repurchases, with the remainder going to debt repayments.
The company said the Biosciences and Diagnostic Solutions business in its Life Sciences segment was separated from BD and combined with Waters Corporation on February 9, 2026. It said the historical results of the business will be reflected as discontinued operations after the separation, and the Life Sciences segment will be eliminated from reporting, leaving 4 reportable segments.
BD said tariffs adversely impacted its operating expenses in Q1 of fiscal 2026. Based on tariffs currently in effect, the company expects a continued adverse impact to operating expenses for fiscal 2026 and potentially beyond, primarily on products or components imported from countries in its global supply chain that have no exemption opportunities.

Key figures

Quarter ended December 31, 2025

Revenue: $5.3B
Operating income: $552M
Net income: $382M
EPS: $1.34
Operating cash flow: $657M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Quarterly Revenue and Operating Cash Flow

BD said worldwide revenues rose 1.6% to $5.252 billion for the 3 months ended December 31, 2025, compared with the prior-year period. Operating cash flow for the first 3 months of fiscal 2026 was $657 million.

Source · Based on the MD&A text of the filing

Dividends, Share Repurchases and Waters Cash Distribution Plans

The company paid cash dividends of $299 million to common shareholders in the first 3 months of fiscal 2026 and repurchased about $250 million of common stock. It said it expects to use about $2 billion of the cash distribution received in the Waters transaction for accelerated share repurchases, with the remainder going to debt repayments.

Source · Based on the MD&A text of the filing

Separation of Biosciences and Diagnostic Solutions and Segment Changes

The company said the Biosciences and Diagnostic Solutions business in its Life Sciences segment was separated from BD and combined with Waters Corporation on February 9, 2026. It said the historical results of the business will be reflected as discontinued operations after the separation, and the Life Sciences segment will be eliminated from reporting, leaving 4 reportable segments.

Source · Based on the MD&A text of the filing

Tariff Impact and Company Outlook

BD said tariffs adversely impacted its operating expenses in Q1 of fiscal 2026. Based on tariffs currently in effect, the company expects a continued adverse impact to operating expenses for fiscal 2026 and potentially beyond, primarily on products or components imported from countries in its global supply chain that have no exemption opportunities.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.